Palobiofarma S.l.

Medibiofarma, S.l.

Juan Camacho Gómez

Julio Cesar Castro Palomino Laria

Rodolfo Rodríguez Iglesias

Julio Castro Palomino Laria

Julio Cesar Castro-Palomino Laria

Adela Mendoza Lizaldez

Julio Castro-Palomino Lária

Abdelaziz El Maatougui

Irene Velilla Martínez

The present invention relates to the cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl) cyclopentane carboxylic acid, a process for obtaining said cocrystals, combination products and pharmaceutical compositions comprising said cocrystals and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by Aadenosine receptor antagonism.

Cocrystals of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid

The present invention relates to novel, optionally substituted, N-benzyl-2-phenoxybenzamide derivatives of formula (I), as modulators of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2), to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of EP4 and/or EP2 receptors of prostaglandin E2 (PGE2) such as cancer disease, pain, inflammation, neurodegenerative diseases and kidney diseases.

N-benzyl-2-phenoxybenzamide derivatives as prostaglandin E2 (PGE2) receptors modulators

The present invention relates to novel benzamides derivatives of formula (I) as modulators of PPAR-gamma receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to said compound for use in the treatment of pathological conditions, disorders or diseases that can improve by modulation of PPAR-gamma receptor, such as cancer; metabolic diseases, inflammatory diseases, respiratory disorders, autoimmune diseases, neurodegenerative diseases, cardiovascular diseases and renal diseases.

Benzamide derivatives as PPAR-gamma modulators

The present invention relates to novel heteroaryl amide derivatives of formula (1) as selective inhibitors of histone deacetylase 1 and 2 (hdac1-2) to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition the activity of histone deacetylase class I, particularly HDAC1 and HDAC2, such as cancer, neurodegenerative diseases, Infectious diseases, inflammatory diseases, heart failure and cardiac hypertrophy, diabetes, polycystic kidney disease, sickle cell disease and &#x3b2;-thalassemia disease and to methods for the treatment of the diseases mentioned above.

Heteroaryl amide derivatives as selective inhibitors of histone deacetylases 1 and/or 2(HDAC1-2)

Modulators of the adenosine Areceptors of formula (I): and process for preparing said compounds. Other aspects of the present invention are pharmaceutical compositions comprising an effective amount of said compounds and the use of said compounds in the preparation of a medicament for treating pathological conditions or diseases that can be improved by modulation of adenosine Areceptors.

Adenosine A3 receptor modulators

The present invention relates to the tromethamine salt of (1R,3S)-3-(5-cyano-4-phenyl-1,3-thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid, a process for obtaining said salt, combination products and pharmaceutical compositions comprising said salts and their medical uses, in particular for the treatment or prevention of diseases known to ameliorate by Aadenosine receptor antagonism.

Amine salt of (1R, 3S)-3-(5-cyano-4-phenyl-1,3- thiazol-2-ylcarbamoyl)cyclopentane carboxylic acid

The present invention relates to novel pyridine derivatives of formula (I): as Aadenosine receptor antagonists and ligands of MTmelatonin receptor, to processes for their preparation, to pharmaceutical compositions comprising said compounds and to the use of said for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by antagonizing the adenosine Areceptor and by inhibition of MTmelatonin receptor, such as respiratory disease, metabolic disorders, neurological disorders and cancer.

[object Object]

Modulators of adenosin Areceptors of formula (I): And procedure for preparing these compounds. Other objectives of the present invention are to provide pharmaceutical compositions comprising an effective amount of these compounds and the use of the compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by modulation of the adenosine Areceptor.

Modulators of the adenosine A3 receptors

The present invention relates to novel pyrimidine derivatives of formula (I) as inhibitors of the enzyme phosphodiesterase 10 (PDE-10), pharmaceutical compositions comprising an effective amount of these compounds and the use of the compounds for manufacturing a medicament for the treatment of pathological conditions or diseases that can improve by inhibition of the enzyme Phosphodiesterase 10 such as neurological, psychiatric, respiratory or metabolic diseases.

Growing community of inventors

Barcelona, Spain

Juan Camacho Gómez